Zoledronic Acid News and Research

RSS
Zoledronic acid is a drug used to treat patients with hypercalcemia (high blood levels of calcium) caused by cancer. It is also used together with other drugs to treat multiple myeloma and to prevent bone fractures and reduce bone pain in people who have cancer that has spread to the bone. It is a type of bisphosphonate. Also called zoledronate and Zometa.
The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

Zoledronic acid demonstrates anti-angiogenic effects in metastatic lung cancer

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Osteoporosis drug reduces bone loss in oral cancer

Osteoporosis drug reduces bone loss in oral cancer

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

New osteoporosis drug appears to reduce bone loss in mice with oral cancer

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Denosumab delays skeletal-related side effects in patients with breast cancer and bone metastases

Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium

Results of Adjuvant Treatment with Zoledronic Acid in Stage II/III Breast Cancer to be presented at symposium

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Merrion prepares Phase III study for Orazol in breast cancer treatment

Merrion prepares Phase III study for Orazol in breast cancer treatment

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Denosumab superior to Zometa in preventing SREs in breast cancer patients with bone metastases: Study

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Novartis announces six-year data of Reclast injection for postmenopausal women with osteoporosis

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Amgen granted FDA priority review designation for denosumab BLA

Amgen granted FDA priority review designation for denosumab BLA

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Phase 3 trial demonstrates superiority of Amgen's denosumab over Zometa in preventing SREs

Positive results from new analyses of denosumab Phase 3 trials

Positive results from new analyses of denosumab Phase 3 trials

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Bone-strengthening drug zoledronic acid can help fight breast cancer DTCs: Study

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Amgen submits BLA for denosumab subcutaneous RANK Ligand inhibitor

Merrion Pharmaceuticals increases patent protection for Orazol

Merrion Pharmaceuticals increases patent protection for Orazol

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

RANKL inhibition may prove effective in treatment of human malignancy, suggests study